What is Phase Genomics?
Phase Genomics is a biotechnology firm specializing in advanced genomic analysis. Leveraging proprietary proximity ligation technology, the company enables chromosome-scale genome assembly, metagenomic deconvolution, and the analysis of structural genomic variation and genome architecture. Their offerings include a comprehensive suite of laboratory and computational services and products, such as Hi-C kits for diverse sample types (plants, animals, microbes, and human samples), alongside an industry-leading software platform for genome and metagenome assembly and analysis. Founded in 2015 in Seattle, WA, Phase Genomics was established by a multidisciplinary team of genome scientists, software engineers, and entrepreneurs with the objective of equipping scientists with cutting-edge genomic tools to accelerate groundbreaking discoveries.
How much funding has Phase Genomics raised?
Phase Genomics has raised a total of $7.4M across 4 funding rounds:
Debt
$150K
Debt
$213K
Grant
$5.5M
Other Financing Round
$1.5M
Debt (2020): $150K with participation from PPP
Debt (2021): $213K led by PPP
Grant (2022): $5.5M supported by National Institute of Allergy and Infectious Diseases and Bill & Melinda Gates Foundation
Other Financing Round (2024): $1.5M featuring Bill & Melinda Gates Foundation
Key Investors in Phase Genomics
Bill & Melinda Gates Foundation
Established in 2000 and headquartered in Seattle, Washington, The Bill & Melinda Gates Foundation is an organization that focuses on supporting individuals experiencing hunger and extreme poverty in leading healthier lives.
National Institute of Allergy and Infectious Diseases
The Vaccine Research Center (VRC), is an intramural division of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), US Department of Health and Human Services (HHS). The mission of the VRC is to discover and develop both vaccines and antibody-based products that target infectious diseases.
PPP
Public-Private Partnership
What's next for Phase Genomics?
With the recent influx of major enterprise-level funding and a strategic investment, Phase Genomics is poised for significant expansion and innovation. The company's focus on enabling complex genomic analyses suggests a trajectory towards deeper integration into research and clinical applications. Future developments are likely to involve enhancing their proprietary technology, expanding their service and product portfolio, and forging new strategic alliances within the life sciences and biotechnology industries. This capital infusion will likely fuel further research and development, potentially leading to new breakthroughs in understanding genome architecture and its implications across various biological fields.
See full Phase Genomics company page
